SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-016129
Filing Date
2022-04-27
Accepted
2022-04-27 17:01:18
Documents
54
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vktx-10q_20220331.htm   iXBRL 10-Q 2187971
2 EX-31.1 vktx-ex311_6.htm EX-31.1 20482
3 EX-31.2 vktx-ex312_7.htm EX-31.2 20460
4 EX-32.1 vktx-ex321_8.htm EX-32.1 12581
  Complete submission text file 0001564590-22-016129.txt   7854917

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA vktx-20220331.xsd EX-101.SCH 51399
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vktx-20220331_cal.xml EX-101.CAL 38902
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vktx-20220331_def.xml EX-101.DEF 172909
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE vktx-20220331_lab.xml EX-101.LAB 409165
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vktx-20220331_pre.xml EX-101.PRE 313359
48 EXTRACTED XBRL INSTANCE DOCUMENT vktx-10q_20220331_htm.xml XML 1438903
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

IRS No.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37355 | Film No.: 22860718
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences